ProBioGen Signs Research and License Agreement With Merck

December 11, 2001 — WEST POINT, PA — ProBioGen AG has entered into an exclusive Research and License agreement with Merck & Co., Inc. to explore the development of cell substrates with potential application in the production of biologicals.

The agreement includes an up-front payment, associated success-driven milestone payments and royalties from the net sales of products that may be developed using ProBioGen technology.

The financial terms of the agreement were not disclosed.

POST A COMMENT

Easily post a comment below using your Linkedin, Twitter, Google or Facebook account. Comments won't automatically be posted to your social media accounts unless you select to share.